Stay updated on Nivolumab in AML Prevention Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in AML Prevention Clinical Trial page.

Latest updates to the Nivolumab in AML Prevention Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe Publications section now states that entries are automatically filled from PubMed, and a new revision tag (v3.3.2, 2025-11-19) replaces the previous note and revision (v3.2.0, 2025-10-24).SummaryDifference0.2%

- Check18 days agoChange DetectedTwo new timestamp fields were added: Results First Posted (Estimated) and Last Update Posted (Estimated); these are metadata updates and do not alter substantive study content, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check25 days agoChange DetectedAdded a Results section detailing progression-free survival (PFS), overall survival (OS), non-relapse mortality (NRM), and adverse events, with Results First Posted dates and links to the Informed Consent Form and the Study Protocol / Statistical Analysis Plan.SummaryDifference1%

- Check32 days agoChange DetectedA 'Results Submitted' status has replaced the previous 'No Results Posted' indicator on the study page for REMAIN (NCT02275533). This shows that trial results have been submitted.SummaryDifference0.3%

- Check47 days agoChange DetectedThe page has added aSummaryDifference0.0%

- Check54 days agoChange DetectedMinor update: new dates and two labeled terms added; several old dates removed. Overall, no substantive changes to core content or pricing.SummaryDifference0.6%

Stay in the know with updates to Nivolumab in AML Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in AML Prevention Clinical Trial page.